Скачать книгу

as a consequence of neointimal proliferation inside the BVS Unlike metallic stents, which are powerful light reflectors and induce posterior shadowing and blooming artifacts on the vessel surface, polymeric struts of BVS are transparent to the light so that scaffold integrity, apposition to the underlying wall, and changes in the strut characteristics over time can be easily studied. OCT also showed a very delayed and incomplete resorption of the PLLA stuts. The ABSORB II trial was also the first to report inferiority of ABSORB BVS: three year follow‐up was associated with a twofold greater risk of TLF in comparison with Xience V (10% vs 5%; p = 0.0425). ABSORB III trial demonstrated ABSORB BVS inferiority in terms of overall ST. Cumulative meta‐analyses embracing ABSORB II, ABSORB III, AIDA, EVERBIO II and TROFI II trials indicated higher target lesion failure and overall ST with BVS, especially in ACS and STEMI patients [113–116]. Several large registries, including two national trials (ABSORB JAPAN and ABSORB CHINA)[117–118] demonstrated better outcomes of ABSORB BVS when optimal lesion preparation was combined with final high pressure expansion guided by imaging, avoiding too small arteries. Still the meta‐analyses and the early results of the ABSORB IV trial determined the decision to interrupt production of ABSORB BVS in late 2017 [119]. OCT was instrumental in revealing rational mechanisms for their higher thrombogenicity, including higher strut profiles leading to turbulent flow and low radial strength leading to a smaller and more irregular final lumen areas. Occasionally, malapposed stuts were found to crush inside the lumen creating rare instances of late (up to 3 years) stent thrombosis (ScT). More recently a series of very late (5–7 years) follow‐up studies showed absence of ST at this time point and more consistent disappearance of the bioabsorbable stuts with OCT. Despite the failure of first generation BVS, newer BRS based on different technologies (magnesium) are under current examination with OCT liberally used to optimize initial results and confirm the absence of untoward late changes [120].

      Near‐infrared spectroscopy (NIRS) is widely used in many disciplines to identify the chemical composition of unknown substances. It utilizes the absorbance and reflectance of near‐infrared light from an illuminated targeted area to derive the presence of the target substance. This method is a simple quick technique that provides multiconstituent analysis, and requires no sample preparation or manipulation with hazardous agents [121]. Studies have documented the ability of NIRS to accurately identify lipid‐core atherosclerotic plaques in animal models or autopsy specimens and finally, after in vivo and ex vivo validation studies [122,123], an intraluminal spectroscopy catheter was developed and released for clinical use.

      System description

      Initially, intracoronary NIRS was developed as an independent imaging modality, but a major drawback was the inability to provide spatial orientation to match the lipid content alongside the plaque distribution. However, current co‐registered NIRS‐IVUS catheters (TVC Imaging System, InfraReDx Inc, Burlington, MA, USA) provide data regarding both the vessel structure and the plaque composition.

      After completion of an automatic pullback, data are processed displaying a two‐dimensional map of the vessel, revealing the probability of the presence of a lipid core plaque (LCP), with the pullback position in millimeters on the x‐axis and the circumferential position on the y‐axis. This display is known as the “chemogram.” For each pixel of 0.1 mm and 1°, length and angle respectively, the lipid core probability is calculated from the spectral data collected and semi‐quantitatively coded on a color scale from 0 for red and to 1 for yellow. Whenever a pixel lacks sufficient data, for instance the guidewire is shadowing, the pixel appears black.

      The block chemogram, also created from the NIRS images, combines the results for each 2‐mm section of the artery to create a “virtual block” that summarizes and reflects the probability of LCP intervals. The numeric value of each block produced is the 90th percentile of all pixel values obtained in the corresponding 2‐mm section of the artery in the chemogram. Here, the red coloration indicates a low probability of an LCP, whereas yellow coloration determines a higher probability of an LCP, alongside the intensity of the color reflecting the amount of cholesterol present. In isolation, the block chemogram specifically adapts a four‐color scale method of analysis (red (p < 0.57), orange (0.57 ≤ p < 0.84), tan (0.84 ≤ p < 0.98) and yellow (p ≥ 0.98)) that reflects the probability of the existence of an LCP in each 2‐mm block of pullback which aids the overall visual interpretation. Spectral data are paired with corresponding IVUS frames, overall displayed as a ring around the IVUS image. The lipid core burden index (LCBI) measures the portion of pixels that exceed an LCP probability of 0.6, in all viable pixels within the scanned region, multiplied by 1000. This is a quantitative measure of the intensity of yellow pixels present on the chemogram. The LCBI values vary from 0 to 1000 and the maximum value of LCBI for any of the 4‐mm segments along the analyzed segment is defined as the maxLCBI4mm.

      Potential clinical uses

      Determination of high‐risk plaque

Schematic illustration of a 39-year-old man was admitted with unstable angina.

Скачать книгу